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Abstract
Purpose This systematic reviewwas performed to summarize
published experience using low density lipoprotein particle
number (LDL-P) to monitor the efficacy of lipid-lowering
pharmacotherapies.
Methods Studies were identified from a literature search of
MEDLINE (January 1, 2000 – June 30, 2012); and abstract
searches of select conferences. All accepted studies reported
mean (or median) nuclear magnetic resonance (NMR)-based
LDL-P values for at least 10 subjects receiving lipid lower-
ing pharmacotherapy.
Results Searches revealed 36 studies (with 61 treatment arms)
in which LDL-P measurements were reported pre- and post-
treatment. Most studies also reported changes in low-density
lipoprotein cholesterol (LDL-C), but fewer studies reported
changes in apolipoprotein B (apoB)(n=20) and non-HDL-C
(n=28). Treatments included statins (22 arms/15 studies),
fibrates (7 arms/7studies), niacin (7 arms/6 studies), bile acid
sequestrants (5 arms/2 studies), an anti-apoB oligonucleotide
(2 arms/2 studies), combination therapies (8 arms/6 studies),
anti-diabetics (5 arms/4 studies), and, other treatments (5 arms/2
studies). Lipid-lowering pharmacotherapy resulted in reduc-
tions in mean LDL-P in all but two studies. In several statin
studies, the percent reductions in LDL-P were smaller than
reductions in LDL-C, comparable changes were reported when
LDL-P and apoB, were reported.
Conclusions Study-level data from this systemic review estab-
lish that different lipid lowering agents can lead to discordance
between LDL-P and LDL-C, therefore, basing LDL-lowering
therapy only on the achievement of cholesterol goals may result
in a treatment gap. Therefore, the use of LDL-P for monitoring
lipid-lowering therapy, particularly for statins, can provide a
more accurate assessment of residual cardiovascular risk.
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Introduction
The association between low-density lipoprotein (LDL) par-
ticles and cardiovascular disease (CVD) is well established
[1, 2]. Evidence from lipid lowering clinical trials demon-
strates that LDL lowering therapy reduces cardiovascular
events [3]. Currently, there are number of methods available
commercially to measure LDL. LDL cholesterol (LDL-C)
and non-high-density lipoprotein cholesterol (non-HDL-C)
rely on the cholesterol content of the lipoprotein to measure
the efficacy of LDL-lowering therapy whereas LDL particle
(LDL-P) number and apolipoprotein B (apoB) levels are
used to measure the actual quantity of LDL [3].
LDL particles contain a core of lipid, predominantly choles-
terol esters and aminor amount of triglycerides, surrounded by a
shell of phospholipid on which the major surface protein is
apoB [3]. LDL-C measures the amount of cholesterol packaged
in the LDL particle and has served as the basis for the assess-
ment and management of CVD risk for many years; however, a
number of recent studies have shown that CVD risk may be
better predicted by measuring the concentration of LDL-P [1, 2,
4, 5]. The cholesterol and triglyceride content of LDL particles
vary widely among individuals and can change over time as a
result of lifestyle changes, metabolic disease, and lipid-lowering
therapy. It has been reported that statins, estrogen replacement
therapy, and a low fat/high carbohydrate diet lower the LDL-C
content in LDL particles more than they lower the LDL-P
concentration, while fibrates, nicotinic acid, exercise and a low
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carbohydrate diet lower LDL-P concentration more than they
lower LDL-C content [3]. Thus, reliance on LDL-C rather than
LDL-P as a measure of CVD risk may result in suboptimal
management of LDL-related risk in certain individuals.
In 2011, the National Lipid Association (NLA) held a
consensus conference focused on the use of inflammatory
markers and advanced lipoprotein testing to improve CVD
risk assessment and management of lipid-lowering therapy.
Their consensus statement concluded that measurement of
LDL-P would be a “reasonable measure” to incorporate into
treatment decisions for many patients at intermediate and
high risk treated to LDL-C and non-HDL-C goals in order
to evaluate the adequacy of LDL lowering therapy [6].
However, the panel noted: “additional research is needed to
more clearly define settings in which a policy of treating to
LDL-P goals might produce more favorable outcomes than
the alternative of treating to LDL-C and non-HDL-C goals”.
To assess the utilization of LDL-P measurements for the
management of lipid-lowering therapy, a systematic review
of published studies was conducted which focused on study
level comparisons of treatment-related changes in LDL-P
versus other lipid parameters, including LDL-C, non-HDL-C,
and apoB. We report here study-level correlations between
treatment-related changes in lipid and lipoprotein parameters
and CVD progression.
Materials and Methods
Literature Search and Selection
An electronic search of PubMed was performed using the
following search strategy, where “MeSH” indicates Medical
Subject Headings:
1. Lipoproteins, LDL [MeSH] OR low-density lipoprotein
particle OR LDLOR particle test OR LDL-C OR LDL-P
2. Magnetic Resonance Spectroscopy [MeSH] OR NMR
OR nuclear magnetic resonance
3. #1 AND #2; Limits: English, Human, January 1, 2000 –
July 30, 2012, NOT case reports, letters, editorials, re-
views, new articles
Note that articles available as Epub ahead of print before
the search cut-off date were considered eligible for inclusion;
even if the eventual print publication date was after July 30,
2012. The electronic search was supplemented by manual
searches of 2010 – 2012 abstracts for the annual meetings of
the American College of Cardiology, and American Diabetes
Association, National Lipid Association and American Heart
Association (2010 and 2011 conferences only), (screened
first by title and then by review of the complete abstract)
and a limited manual search of reference lists from accepted
studies and recent reviews.
Studies of any design (prospective or retrospective, ran-
domized or non-randomized) were selected for review if they
reported mean (or median) magnetic resonance-based LDL-P
values for at least 10 patients prior to and after receiving lipid-
lowering pharmacotherapy; studies reporting LDL-P changes
only after nutritional supplements or lifestyle changes (exer-
cise, diet, smoking cessation) were not included. Screening
was performed by a single reviewer. Multiple publications of
the same or overlapping series of patients were identified and
grouped together as a “kinned” citation; the parent study was
most often the most recent publication. Data from kinned
studies were counted only once to avoid the double-counting
of patients.
Extraction of Study-Level Variables
Data were extracted by two independent reviewers and dis-
crepancies resolved by consensus conference. The following
data elements were sought from each accepted study: study
characteristics, including PMID number, first author, geo-
graphic location by country, publication year, study type [case
series, cohort, Randomized Control Trial (RCT)], and lipid
lowering treatment [generic drug name, dose, and treatment
duration; population characteristics, including underlying
condition(s) requiring lipid-lowering therapy, number of sub-
jects enrolled, mean/median age, gender distribution, racial
distribution, and number of subjects with CVD, present family
history of CVD, diabetes, metabolic syndrome, smoking,
hypertension (blood pressure >140/90 mm Hg or on medica-
tion), obesity (bodymass index≥35 kg/m3); and LDL-P, and if
available, LDL-C, HDL-C, non-HDL-C, and apoB prior to
and after lipid-lowering treatment; and if reported, CVD out-
comes and changes in atherosclerotic plaque burden (carotid
intima media thickness (CIMT), coronary artery calcium
(CAC) score) and/or correlations of changes in LDL-P and
CVD outcome and changes in atherosclerotic plaque burden.
On-treatment results for LDL-C, apoB and non–HDL-C
are expressed in milligrams per deciliter and LDL-P in
nanomoles per liter. In addition, each parameter is expressed
in terms of population percentiles based on data from the
Framingham Offspring Study [7].
Study, patient, and test-level data were summarized using
general descriptive statistics (means, standard deviations,
ranges, counts) and subgroup analyses were performed by
type of lipid-lowering therapy.
Results
Search Yields
From the PubMed search, a total of 653 citations were
screened and 320 full publications were retrieved for further
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review (Fig. 1). Manual searches of bibliographies and re-
cent reviews yielded 51 additional studies, and manual
searches of annual meeting abstracts yielded 4 additional
studies (reported only as abstracts) for further review. From
these, a total of 36 primary studies reported treatment-
induced changes in mean (or median) NMR-derived LDL-P
values following lipid-lowering pharmacotherapy. These
studies served as the basis for this analysis. In addition
to LDL-P, most accepted studies also reported changes in
mean (or median) LDL-C (31 studies), non-HDL-C (28
studies) and/or apoB (20 studies). Baseline concentrations of
LDL-P have been reported for the Medical Research
Council/British Heart Foundation Heart Protection Study, one
of the largest randomized control trials of statin therapy to date,
however LDL-P was not measured following treatment so this
study was not included.
Study and treatment characteristics are summarized
in Table 1. Mean (or median) nuclear magnetic reso-
nance (NMR)-based LDL-P values were reported pre- and
post-treatments with statins (1876 subjects in 22 treat-
ment arms), fibrates (788 subjects in 7 arms), niacin
(580 subjects in 7 arms), bile acid sequestrants (139
subjects in 5 arms), combination therapies (1342 subjects
in 8 treatment arms), anti-apoB oligonucleotide therapy (104
subjects in 2 treatment arms), anti-diabetic therapies (848
subjects in 5 treatment arms) and other treatments (717 sub-
jects in 5 treatment arms). Most studies were short-term (me-
dian of 3 months per treatment arm), randomized con-
trolled trials (28), and designed to demonstrate lipid
lowering for primary prevention (27/36). Only four
studies reported CVD outcomes.
Treatment-Induced Changes in Lipid Parameters
Results from 36 studies are summarized in Tables 2, 3, 4, 5,
6, 7, 8, and 9. Reductions in LDL-P were observed with all
treatments except for two (one fibrate, one anti-diabetic).
Similarly, LDL-C was reduced with all treatments except
for the fibrates, anti-diabetic therapy and the cholesteryl
ester transfer protein (CETP) inhibitor dalcetrapib. Of the
marketed lipid-lowering monotherapies studied, statins pro-
duced the greatest reductions in LDL-P and LDL-C, followed
by niacin, fibrates and bile acid sequestrants. In addition, the
combination of statins with other agents yielded an even
greater effect on LDL-P and LDL-C. The effects of each type
of lipid-lowering or anti-diabetic therapy on LDL-P and LDL-C
are discussed below in terms of average results across all studies
within each drug class, not accounting for differences in the
agent, dose, time period, size of the treatment group or charac-
teristics of the population at baseline.
Statins
A total of 1,876 subjects were treated with statins for a mean
of 4 months (range 1–12 months). Most subjects had hyper-
cholesterolemia or mixed dyslipidemia with or without
known CVD; two studies featured subjects with metabolic
syndrome or diabetes. The types of statins studied included:
atorvastatin (A) in 8 treatment arms [8–14], pravastatin (P) in
6 arms [13, 15–19], simvastatin (S) in 8 arms [9, 13, 20–22],
rosuvastatin (R) in 3 arms [9, 12], and pitavastatin (Pit) in 1
arms [17]. The mean LDL-P and LDL-C concentrations at
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Fig 1 Study flow diagram
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respectively (Table 2). The mean treatment-induced de-
crease in LDL-P across studies was 30 % producing an
on-treatment level of 1346±226 nmol/L which is equiv-
alent to the 42nd percentile of the Framingham Offspring
reference population. This was slightly less than the mean
decrease in LDL-C (−34 %), which yielded an on-treatment
level of 106±27 mg/dL (29th percentile), and the mean de-
crease in non-HDL-C (−34 %, 35th percentile). The mean on-
treatment apoB level was 103±21 mg/dL (54th percentile)
which represented a 27 % decrease from baseline. These
results suggest that statins reduce LDL-C to a lower popula-
tion percentile however, both LDL-P and apoB levels
remained at elevated population percentiles signifying poten-
tially higher residual cardiovascular (CV) risk.
Fibrates
Results from 7 studies of fibrate treatments involving 788
subjects with hypertriglyceridemia or known CVD are
presented in Table 3. These included 4 studies with
fenofibrate (F) [9, 21, 23, 24], 2 with bezafibrate (Bz) [25,
26] and one with gemfibrozil (G) [4]. Unlike statins, fibrates
were found to increase LDL-C in most studies (mean +6 %)
whereas LDL-P, non-HDL-C and apoB were reduced in most
fibrate studies (mean decreases of 10 %, 14 % and 6 %
respectively). The average population percentiles achieved
for LDL-C, non-HDL-C and apoB were 44 %, 54 %, and
56 %, respectively. In contrast, the average on-treatment
percentile achieved for LDL-P was 57 %. This highlights
distinct differences in these biomarkers representing LDL-
related risk for CVD.
Niacin
Niacin was evaluated in a total of 580 subjects enrolled
across 6 studies (Table 4) [10, 27–33]. Baseline LDL-P
and LDL-C levels were quite variable ranging from 1033
to 2561 nmol/L for LDL-P and 76 to 211 mg/dL for
LDL-C. Small decreases (≤ 20 %) were observed in all
LDL-related parameters with treatment. The mean pop-
ulation percentiles achieved on-treatment for LDL-P and
LDL-C were 51 % and 53 % however in 2 studies,
population percentiles for LDL-P of below 20 % were
achieved [28, 31].
Table 1 Summary of study and patient characteristics
Parameter Total studiesa Combination therapy Type of pharmacotherapyb
Statins Fibrates Niacin Bile acid Sequestrant Anti-diabetic
Number of studies 36 6 15 7 6 2 4
Number of treatment arms 61 8 22 7 7 5 5
Number of patients 6394 1342 1876 788 580 139 848
Study type:
Cohort/other 8 0 3 3 1 1 0
RCT 28 6 12 4 5 1 4
Study population
Primary prevention 27 2 11 4 4 2 3
Secondary prevention 9 1 4 1 2 0 0
Median treatment per arm (months) 3 4 3 3 3 1.5 5
Range (months) 1 – 36 1 –12 1–12 1 – 12 3 – 12 1.0 – 1.5 3 – 6
Arms reporting pre-post changes in
LDL-P 36 8 22 7 7 5 5
LDL-C 31 6 17 5 6 5 5
apoB 20 6 14 3 4 1 2
Non-HDL-C 28 6 16 5 5 1 5
Studies reporting CVD outcomes
CVD events 1 0 0 1 0 0 0
Change in atherosclerotic plaque 3 0 1 1 0 0 0
RCT Randomized Control Trial; LDL-P low-density lipoprotein particle number; LDL-C low-density lipoprotein cholesterol; apoB apolipoproteinB;
Non-HDL-C non-high-density lipoprotein cholesterol; CVD cardiovascular disease
a some studies had treatment arms for more than one type of pharmacotherapy;
b excludes two studies of an anti-apoB oligonucleotide and two studies of statin therapy noted only as aggressive or standard treatment and
pravastatin and dalcetrapib at 300, 600 and 900 mg;
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Bile acid Sequestrants
The bile acid Sequestrants colesevelam (Colv) and colestimide
(Cole) were evaluated in 2 studies involving a total of
139 hypercholesterolemic subjects (Table 5) [34, 35].
Baseline LDL-P and LDL-C mean levels were significantly
elevated (2206±164 nmol/L and 178±13 mg/dL, respective-
ly). Both levels were decreased 9 % on treatment.
Anti-ApoB Oligonucleotides
Two studies reported results of treatment with the experi-
mental injectable anti-apoB oligonucleotide mipomersin
(Table 6) [36, 37]. One study was conducted in patients with
familial hypercholesterolemia [36]; the other in statin-
intolerant patients with high CVD risk [37]. Significant
decreases in all LDL-related parameters were reported
(mean −41 to −48 %). The average population percentiles
achieved for LDL-C, non-HDL-C and apoB were 47 %,
45 %, and 53 %, respectively. In contrast, the average on-
treatment percentile achieved for LDL-P was 28 %. Thus,
LDL-P goals were closer to being achieved with treatment
than LDL-C, non-HDL-C and apoB goals.
Combination Therapies
Therapies involving combinations of statins with one or
more lipid lowering agent including niacin [20, 29],
fenofibrate [9], ezetimibe [29] or prescription omega-3-
fatty acid [11], pioglitazone [38], were evaluated in 1342
subjects across 6 studies (Table 7). On treatment, LDL-P and
LDL-C were reduced 34 % and 35 %, to levels equivalent to
the 27th and 13th percentiles of the reference population,
respectively. Similar reductions in non-HDL-C (21 %) and
apoB (35 %) were also observed. The most effective therapy
was the combination of simvastatin with ezetimibe and nia-
cin which decreased LDL-P and LDL-C by 48 % and 60 %,
levels equivalent to the 10th and 2nd population percentiles,
respectively [29].
Anti-diabetic agents
Results from 4 studies evaluating anti-diabetic therapies in
subjects with metabolic syndrome or type 2 diabetes mellitus
(T2D) are presented in Table 8. These included pioglitazone
(3 treatment arms) [39–41], rosiglitazone (1 arm) [39] and
metformin (1 arm) [42]. Overall, mean reductions in LDL-P
and LDL-C were small (4–5 %).
Other lipid-lowering therapies
Two studies reported results from lipid-lowering therapies
that could not be classified in the aforementioned treatment
groups (Table 9). These included the Stop Atherosclerosis
in Native Diabetics Study (SANDS) [43] and a study
evaluating the CETP inhibitor dalcetrapib [44]. SANDS
compared the effects of aggressive treatment to LDL-C
and non-HDL-C targets vs. standard treatment. The ag-
gressive treatment, consisting of statins, alone or in
combination with other agents, decreased LDL-C and LDL-
P to desired population percentile goals (<2 % and 7 %,
respectively) whereas the standard treatment had little effect.
In the dalcetrapib study in which subjects had LDL-
C<100 mg/dL but elevated LDL-P levels at baseline, treat-
ment at the highest dose decreased LDL-P 10 % to a level
equivalent to the 26th population percentile.
Medication, LDL-C and LDL-P Goals
Each study was evaluated to determine whether the follow-
ing treatment goals recommended for high risk patients were
met [45]: LDL-P≤1000 nmol/L and LDL-C<100 mg/dL. In
the statin monotherapy studies, LDL-P goals were met in
4 % (1/22) of study arms and LDL-C goals met in 53 %
(9/17) of study arms in which patients were above goal at
initiation of treatment. In the niacin treatment group, LDL-P
and LDL-C goals were met in 29 % (2/7) and 33 % (2/6) of
study arms, respectively. In the statin combination therapy
treatment group, LDL-P goals were met in 28 % (2/8) of
study arms and LDL-C goals were met in 67 % (4/6) of
treatment arms in which patients were above goal at initia-
tion of treatment. In addition, LDL-C and LDL-P goals were
met with aggressive, but not standard treatment, in SANDS.
None of the other lipid-lowering therapies resulted in the
attainment of LDL-P and LDL-C goals.
Furthermore, as illustrated in Fig. 2, these responses are
expressed in terms of percentile of the population achieved
for each lipid lowering therapy. Various treatment options
(except niacin) reduced LDL-C to a lower population percen-
tile versus LDL-P suggesting possible residual CV risk with
elevated LDL-P levels.
Correlation of Lipid Parameters and CVD Progression
Three studies examined correlations between treatment-
induced changes in lipid parameters and atherosclerosis pro-
gression [25, 43, 46] and one study examined correlations
between changes in lipid parameters and new coronary
events [4].
In the Pravastatin Limitation of Atherosclerosis in the
Coronary Arteries (PLAC-I) Trial, 241 patients with angio-
graphically defined coronary artery disease were randomized
to treatment with 40 mg/day pravastatin or placebo [46].
Statin-treated subjects showed a 25 % decrease in LDL-P
and 26 % decrease in LDL-C over 6 months and a signifi-
cantly slower rate of lumen narrowing over 3 years compared








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cardiovasc Drugs Ther (2013) 27:465–479 475
to placebo controls (−0.018 vs. −0.053 mm/year, p<0.01).
Correlation of 6-month lipid levels and atherosclerosis pro-
gression showed that lumen narrowing was associated with
higher on-study LDL-P (r=−0.13), independent of on-study
LDL-C, HDL-C, and triglycerides.
In SANDS, 418 Native Americans with diabetes and no
previous cardiovascular events were randomized to 1) ag-
gressive statin treatment to targets of LDL-C ≤70 mg/dL,
non-HDL-C ≤100 mg/dL, and systolic blood pressure
(SBP) ≤115 mm Hg or 2) standard statin treatment to
targets of LDL-C ≤100 mg/dL, non-HDL-C ≤130 mg/dL,
and SBP ≤130 mm Hg [43]. CIMTwas assessed as a measure
of the severity of atherosclerosis. Most patients had been
treated previously and had achieved standard targets at base-
line (mean LDL-C of 103 and 102 mg/dL, mean non-HDL-C
of 136 and 137 mg/dL, and mean SBP of 128 and 132 mmHg
for the aggressive and standard groups, respectively). After
36 months of treatment, the aggressive group had achieved
significantly greater reductions in LDL-P (−30 % vs. −8 %),
LDL-C (−31 % vs. +2 %), non-HDL-C (−26 % vs. +1 %),
apoB (−26 % vs. −6 %) and a significant reduction in lumen
narrowing (−0.020 vs. +0.038 mm) compared to the standard
group. A comparison of changes in CIMT between the two
groups, stratified by baseline lipid levels, showed no sig-
nificant interactions between treatment and initial levels of
LDL-P, LDL-C, non-HDL-C, HDL-C, triglycerides, or apoB
indicating that the treatment effect did not differ by baseline
levels of themeasured lipid parameters. Further analysis found
that changes in LDL-C and non-HDL-C were both indepen-
dently correlated with CIMT regression, while changes in
LDL-P and apoB showed borderline significance to CIMT
regression at 36 months.
In the Veterans Affairs High-Density Lipoprotein
Intervention Trial (VA-HIT), 1061 men with a diagnosis of
established coronary heart disease (CHD) were randomized to
1200 mg/day gemfibrozil or placebo and treated for a median
of 5.1 years. On-study lipid levels, obtained at the 7-month
visit, showed significant increases in HDL-C (+6 % vs. 0 %)
and HDL-P (+10 % vs. +6 %) and significant decreases in
triglycerides (−30 % vs. +6 %), non-HDL-C (−5 % vs. +1 %),
apoB (−6 % vs. −3 %), and LDL-P (−5 % vs. +7 %) for the
gemfibrozil group compared to the placebo group [4]. Among
those patients who had a coronary event, baseline and treat-
ment levels of LDL-P were strong independent predictors of a
new coronary event, while neither baseline nor on-study levels
of LDL-C, HDL-C, or triglycerides were significant predictors
of CHD risk.
Discussion
The objective of this analysis was to determine the effect of
different LDL-lowering therapies on various LDL markers.
Study-level correlations between treatment-related changes
in lipid parameters and CVD progression were reported, as
well as the population percentile achieved based on data
from the Framingham Offspring Study. Among the lipid-
lowering monotherapies studied, the anti-apoB therapy
(mipomersen) and the statins produced the greatest reduc-
tions in LDL-P and LDL-C, followed by niacin, fibrates
and bile acid sequestrants. Furthermore, the combination
of statins with other agents led to greater reductions in
LDL-P and LDL-C than the statins alone. Although the
combination of fibrates with statins generally decrease
LDL-C and LDL-P levels (Table 7), the effect can vary
and increases in these parameters have been observed in
certain populations [47]. Studies evaluating omega-3-fatty
acids as monotherapy were beyond the focus of this review
however, a study was published reporting the effects of a pure



































Fig. 2 Percentile population
achieved with therapy. The mean
percentile of the reference
population achieved with each
treatment is shown. (+/− SEM)
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lipoprotein particles in hypertiglyceridemic patients. This
study showed that in subjects treated with 4 g/day IPE for
12 weeks, changes in LDL-P (−0.1 %) and LDL-C (−6.5 %)
from baseline were negligible [48].
Therapies targeting LDL-C are easily evaluated in routine
clinical practice because of the widespread availability of
LDL-C measurements; LDL-C is most commonly estimated
from measurements of total cholesterol using the Friedewald
formula. However, as illustrated in this analysis, various
treatment options demonstrated variable effects on LDL-C
relative to LDL-P. Study-level data from this systematic
review showed that statins generally lower LDL-C more than
they lower LDL-P, whereas fibrates lower LDL-P more than
they lower LDL-C. Therefore, reliance on only LDL-C as a
biomarker of LDL-related risk of CVD may not fully appre-
ciate the benefit of these therapies due to the fact that LDL-C
and LDL-P may not agree at times and are considered dis-
cordant measures.
Why is there discordance between LDL-C and LDL-P?
The cholesterol content of LDL particles varies between
individuals owing to differences in the relative content of
cholesteryl ester and triglycerides within the core of LDL
particles [3, 49]. The majority of atherogenic lipoproteins in
individuals with insulin resistance, metabolic syndrome or
T2D are smaller, cholesterol-depleted LDL particles. These
compositional changes in LDL particles may lead to a dis-
agreement between measures of LDL-C and LDL-P resulting
in “discordance” [2]. As demonstrated in this analysis, statins
tend to lower LDL-C more than LDL-P, hence creating dis-
cordance whereby LDL-C targets may be achieved while
LDL-P levels remain elevated. This indicates the potential
for residual CVD risk.
The clinical consequences of discordant measures of
LDL-P and LDL-C have been investigated in MESA [2]
and the Framingham Offspring Study [1]. In both studies,
in individuals with discordant LDL-P and LDL-C levels, it
was LDL-P and not LDL-C that tracked well with CVD risk.
This systematic review also identified 2 randomized con-
trolled trials that reported correlations between lipid and lipo-
protein parameters and CVD progression. A strong correlation
between on-study LDL-P and CVD progression was observed
in the PLAC-1 trial which found that lumen narrowing was
associated with higher on-study LDL-P, independent of LDL-C,
HDL-C, and triglycerides [46]. In addition, the VA-HIT
study found that on-study LDL-P was a strong, independent
predictor of new coronary events, while on-study LDL-C,
HDL-C, and triglycerides were not significant predictors of
CVD risk [4]. Overall, these results are consistent with
study-level analyses from several large epidemiologic studies,
including the EPIC-Norfolk [50, 51], Framingham Offspring
[1], MESA [2], and Women’s Health studies [5, 15], which
found that LDL-P was a better discriminator of cardiovascular
risk than LDL-C.
Lipoprotein Management
Measurement of LDL-P levels is recommended for high-risk
patients whose LDL-C levels are optimal, near optimal or
borderline-high, but who also have additional CHD risk equiv-
alents. These include patients with CVD, metabolic syndrome
or T2D that are near or at a LDL-C goal of >70 mg/dL
and <100 mg/dL; or patients with metabolic syndrome, low
HDL-C levels or T2D near or at a goal of LDL-C <100 mg/dL.
What therapeutic targets should be established for apoB,
LDL-C, non-HDL-C, and LDL-P in these patients? The
American Association of Clinical Chemistry (AACC) suggest
the following goals: apoB <80 mg/dL, LDL-C <100 mg/dL,
non-HDL-C <120 mg/dL and LDL-P <1100 nmol/L [6, 52].
When a patient is at or near their LDL-C goal with discor-
dantly high LDL-P, then one can conclude that the patient has
residual LDL-related risk and more intense LDL lowering
therapy is needed. Conversely, when LDL-P levels are
within the target range, then current therapy is adequate [3].
Therefore, the information gleaned from the LDL-P con-
centration should be utilized to aid clinical decision-making
regarding drug choice and dosing. This can be especially
helpful with regard to combination therapies which differ-
entially affect LDL-C and LDL-P [44].
Perspectives and Future Directions
In this study, we conducted a systematic review that reports
the effects of multiple classes of lipid modifying agents on
LDL-C and LDL-P. In the future, new classes of LDL-C
lowering therapies will further challenge the use of the
Friedewald formula to calculate LDL-C levels. Certain med-
ications that inhibit CETP [53] and proprotein convertase
subtilisin/kexin type 9 (PCSK9) [54] have reported limita-
tions of the LDL-C estimation by the Friedewald formula,
which overestimates the LDL-C lowering effect of these
agents when compared to standardized ultracentrifugation
methods (beta quantification). These obstacles may be over-
come by measuring LDL-P and/or apoB.
LDL-P measurements provide more accurate information
concerning risk stratification in most studies, and a potential
target to guide adjustment for LDL-C lowering therapy.
Among subjects with LDL-C at their minimal acceptable
goal, an elevated LDL-P would confer risk that may be
reduced by adjustment of the statin dosage, change in statin
from a less efficacious to more efficacious agent, or the
addition of a further LDL-P lowering agent. Contemporary
lipid lowering management practices tend to overtreat with
statins, particularly for intermediate and high risk patients, to
LDL-C values that are pushing beyond 70 mg/dL. The use of
LDL-P as a management target in the presence of discor-
dantly high LDL-P values can individualize aggressive lipid-
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lowering therapy and in the process potentially reduce statin
intolerance and be more cost-efficient. In addition, patients
with LDL-C above their minimal acceptable target who have
low LDL-P may not need intensification of their cholesterol
lowering therapies.
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